Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 9/20 | 0.50 |
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583856 | 1.00 | PPARA (0.54) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL25054171 | 1.00 | PPARA (0.54) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL16279350 | 1.00 | PPARA (0.54) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL16279348 | 1.00 | PPARA (0.54) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL16279346 | 1.00 | PPARA (0.54) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL16286030 | 0.92 | ACE (0.49) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL16278873 | 0.91 | PPARA (0.52) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL28160690 | 0.91 | PPARA (0.52) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL16278874 | 0.91 | PPARA (0.52) | PPARAPPARGPIN1ACECTSS | |
| SCHEMBL3819136 | 0.90 | CTSS (0.54) | PPARAPPARGPIN1ACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021062030-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-1165501-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051975-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | PPARA 1648/4885PPARG 1019/4885PIN1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.